A vasodilating β1 blocker celiprolol inhibits muscular release of uric acid precursor in patients with essential hypertension.
Although nonvasodilating β1 blockers increase the levels of uric acid in serum, it is not known whether vasodilating β1 blockers have a similar effect. In the present study, we evaluated the effect of celiprolol on the release of hypoxanthine, a uric acid precursor, from muscles after an exercise. We used the semi-ischemic forearm test to examine the release of lactate (ΔLAC), ammonia (ΔAmm), and hypoxanthine (ΔHX) before and 4, 10, and 60 min after an exercise in 18 hypertensive patients as well as 4 normotensive subjects. Before celiprolol treatment, all the levels of ΔHX and ΔAmm, and ΔLAC were increased by semi-ischemic exercise in hypertensive patients, and the increases were remarkably larger than those in normotensive subjects. Celiprolol decreased both systolic and diastolic pressure. It also decreased the levels of ΔHX and ΔAmm without changes in ΔLAC after an exercise. These findings also were confirmed by summation of each metabolite (ΣΔMetabolites). Celiprolol caused a marginal decrease of serum uric acid, but the difference was not statistically significant. On the other hand, nonvasodilating β1 blockers did not suppress the levels of ΔHX and ΔAmm, whereas they significantly increased ΔLAC after an exercise. Celiprolol improved energy metabolism in skeletal muscles. It suppressed HX production and consequently did not adversely affect serum uric acid levels.
Division of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, Yonago, Japan.
E
E
Mizuta
S B
SB
Utami
A
A
Ohtahara
S
S
Endo
M
M
Mishima
A
A
Hasegawa
K
K
Yamada
M
M
Kato
K
K
Yamamoto
K
K
Ogino
H
H
Ninomiya
S
S
Miyazaki
T
T
Hamada
S-i
SI
Taniguchi
J
J
Cheng
I
I
Hisatome
D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D017272:Celiprolol / Q000494:pharmacology / Q000627:therapeutic use*; D005080:Exercise Test; D005260:Female; D005542:Forearm / Q000098:blood supply / Q000473:pathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D019271:Hypoxanthine / Q000378:metabolism*; D007511:Ischemia / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D014527:Uric Acid / Q000097:blood*; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D058671:Adrenergic beta-1 Receptor Antagonists; D014665:Vasodilator Agents; D014527:Uric Acid; D019271:Hypoxanthine; D017272:Celiprolol